Dr Charlotte Bradbury and RCP academic vice-president Professor Cheng-Hock Toh summarise the recent trials on heparin anticoagulation for patients admitted to hospital with COVID-19.
The summary explains the current picture while awaiting full peer-reviewed results, and emphasises that any decisions regarding anticoagulation for individual patients should incorporate a risk assessment for bleeding as well as additional thrombotic risk factors.